Physician profile
Scott A Williams
NPI 1508992140
$1,732.17
in general payments reported to CMS, 2019-2025
30 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Adult Health (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $186).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $610 · 2022: $580 · 2023: $173 · 2024: $178 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $542.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $502.00 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $156.42 | 2022-2024 | |
| Lilly USA, LLC | $129.46 | 2021-2023 | Trulicity |
| Solventum Corporation | $110.17 | 2025 | Prevena, Activ.A.C., V.A.C. Veraflo Cleanse Choice |
| Paratek Pharmaceuticals, INC. | $100.38 | 2023-2025 | Nuzyra |
| Astrazeneca Pharmaceuticals Lp | $89.13 | 2021-2024 | Breztri |
| Otsuka America Pharmaceutical, INC. | $80.62 | 2022-2024 | Rexulti |
| Mylan Specialty L.P. | $72.34 | 2021-2022 | |
| Amgen INC. | $44.03 | 2023-2024 | Repatha, Otezla |
| Xeris Pharmaceuticals, INC. | $42.43 | 2021-2022 | |
| Novo Nordisk INC | $42.34 | 2021-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $32.47 | 2021 | |
| Biogen, INC. | $30.17 | 2021 | |
| Electromed, INC. | $27.07 | 2022 | |
| Sunovion Pharmaceuticals INC. | $20.43 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20.08 | 2022 | |
| Scilex Pharmaceuticals INC. | $19.91 | 2021 | |
| Baxter Healthcare | $19.77 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Neurocrine Biosciences, INC. | $19.44 | 2023 | |
| Alkermes, INC. | $18.85 | 2021 | |
| Allergan, INC. | $18.69 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.76 | 2022 | |
| Seqirus USA INC | $15.94 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Novartis Pharmaceuticals Corporation | $15.94 | 2023 | |
| Janssen Pharmaceuticals, INC | $15.82 | 2021 | |
| Redhill Biopharma INC. | $15.68 | 2021 | |
| Nestle Healthcare Nutrition INC. | $15.47 | 2021 | |
| Merck Sharp & Dohme LLC | $15.10 | 2024 | Verquvo |
| Astellas Pharma US INC | $12.94 | 2021 | |
| Adlon Therapeutics L.P. | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.